Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
With
American Society of Health-System Pharmacists
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
non-pregnant adult patients
between 18-75 years of age
are seen in the UCH outpatient cancer clinics for management of solid tumor and/or non-leukemia malignancies
are prescribed high dose dexamethasone for CINV for no longer than 5 days, and
have an absolute neutrophil count (ANC) \> 1,500/mm3 and platelet count \> 100,000/mm3 at time of glucose sensor placement.
ANC of 1,500/mm3 is standard criteria for receiving outpatient chemotherapy.
You may not be if
leukemia-type malignancy
require inpatient administration of chemotherapy
are receiving chronic steroids
have an ECOG/WHO/Zubrod score of 3 or 4
have an ANC \< 1,500 cells/mm3 at time of CGM device placement or are anticipated to have a decrease in ANC \< 1,500 cells/mm3 during 5 days after sensor placement,
have an active infection, or have significant cognitive impairment limiting their ability to use the CGM or complete a take-home diary.
to further minimize the potential for infection, patients receiving chemotherapy regimens associated with a high (\>20%) risk of febrile neutropenia, according to the 2014 NCCN guidelines, will also be excluded from study
Clareo Health | Glucose Variability in Cancer Patients Receiving Dexamethasone
